Your browser doesn't support javascript.
loading
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
Wittert, Gary; Bracken, Karen; Robledo, Kristy P; Grossmann, Mathis; Yeap, Bu B; Handelsman, David J; Stuckey, Bronwyn; Conway, Ann; Inder, Warrick; McLachlan, Robert; Allan, Carolyn; Jesudason, David; Fui, Mark Ng Tang; Hague, Wendy; Jenkins, Alicia; Daniel, Mark; Gebski, Val; Keech, Anthony.
Afiliación
  • Wittert G; Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA, Australia; South Australian Health and Medical Research Institute, Adelaide, SA, Australia. Electronic address: gary.wittert@adelaide.edu.au.
  • Bracken K; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
  • Robledo KP; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
  • Grossmann M; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Department of Endocrinology, Austin Health, Melbourne, VIC, Australia.
  • Yeap BB; Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia.
  • Handelsman DJ; ANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, NSW, Australia.
  • Stuckey B; Medical School, University of Western Australia, Perth, WA, Australia; Keogh Institute for Medical Research, Perth, WA, Australia; Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Conway A; ANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, NSW, Australia.
  • Inder W; Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • McLachlan R; Hudson Institute of Medical Research and Monash University, Clayton, VIC, Australia.
  • Allan C; Hudson Institute of Medical Research and Monash University, Clayton, VIC, Australia.
  • Jesudason D; Department of Endocrinology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.
  • Fui MNT; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Department of Endocrinology, Austin Health, Melbourne, VIC, Australia.
  • Hague W; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
  • Jenkins A; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
  • Daniel M; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Health Research Institute, University of Canberra, Canberra, ACT, Australia.
  • Gebski V; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
  • Keech A; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Lancet Diabetes Endocrinol ; 9(1): 32-45, 2021 01.
Article en En | MEDLINE | ID: mdl-33338415
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estado Prediabético / Testosterona / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Etiology_studies Límite: Aged / Humans / Male / Middle aged País/Región como asunto: Oceania Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estado Prediabético / Testosterona / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Etiology_studies Límite: Aged / Humans / Male / Middle aged País/Región como asunto: Oceania Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido